Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-19T22:15:34.634Z Has data issue: false hasContentIssue false

Chapter 18 - Testosterone, gonadotropins, and genetic polymorphisms in men with Alzheimer's disease

from Section 4 - Possible genetic factors related to hormone treatment effects

Published online by Cambridge University Press:  06 July 2010

Eef Hogervorst
Affiliation:
Loughborough University
Victor W. Henderson
Affiliation:
Stanford University, California
Robert B. Gibbs
Affiliation:
University of Pittsburgh
Roberta Diaz Brinton
Affiliation:
University of Southern California
Get access

Summary

Editors' introduction

This chapter discusses the possibility that men with Alzheimer's disease (AD) exhibit age-accelerated endocrinological change that increases the risk for AD related pathological processes. This age-accelerated endocrinological change is characterized by an earlier decrease in thyroid stimulating hormone, an earlier increase in sex hormone binding globulin, and a subsequent earlier decrease in free or bioavailable testosterone levels. They also show an earlier increase of gonadotropin levels, which may be an appropriate, if inadequate, response to lower free testosterone levels. However, both these processes (the increase in gonadotropin levels as a response to the lowered levels of free testosterone) have the propensity to negatively affect neuronal health, as subsequent chapters in Section 6 will outline in more detail. This acceleration in age-related endocrinological change may be related to stress and morbidity (which are both known to affect thyroid stimulating hormone) and/or possibly, certain genetic polymorphisms that could predispose to an earlier lowering of free testosterone, which, especially when combined with a decrease of androgen receptors in the brain, leads to a lowered protective environment for the aging brain.

Type
Chapter
Information
Hormones, Cognition and Dementia
State of the Art and Emergent Therapeutic Strategies
, pp. 171 - 178
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×